Monoamine Oxidase Inhibitors - Therapeutic use
Research News and Information

Sunday, November 22, 2009

Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.

30 Jul 2009 Neuroprotective therapy has been proposed for age-related neurodegenerative disorders, including Parkinson's disease. Inhibitors of type B monoamine oxidase (MAOB-Is), rasagiline and (-)deprenyl, are the most promising candidate neuroprotective ... Read more...

Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression.

30 Jul 2009 OBJECTIVE: Medication algorithms have been proposed as effective means to offer optimal treatment and improved outcome for patients with severe mental illness. This single-center prospective study compared the efficacy and effects on treatment ... Read more...

Medical treatment of Parkinson disease.

30 Jul 2009 The cardinal characteristics of Parkinson disease (PD) include resting tremor, rigidity, and bradykinesia. Patients may also develop autonomic dysfunction, cognitive changes, psychiatric symptoms, sensory complaints, and sleep disturbances. The ... Read more...

Latest indexed articles for 'Monoamine Oxidase Inhibitors - Therapeutic use'

These are the very latest articles for this heading:

• Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. 30 Jul 2009
• Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. 30 Jul 2009
• Medical treatment of Parkinson disease. 30 Jul 2009
• First-line pharmacotherapies for depression - what is the best choice? 29 Jun 2009
• MAOA gene polymorphisms and response to mirtazapine in major depression. 30 May 2009
• [Combining antidepressants: a useful strategy for therapy resistant depression?] 2 May 2009
• Moclobemide treatment of clozapine-induced hypersalivation: pilot open study. 29 Apr 2009
• Commentary on STAR*D: a summary and UK perspective. 22 Apr 2009
• STAR*D: a summary and UK perspective. 22 Apr 2009
• Neuroprotection trials in Parkinson's disease: systematic review. 13 Apr 2009
• MAO-B inhibitor know-how: back to the pharm. 12 Apr 2009
• Levodopa-related wearing-off in Parkinson's disease: identification and management. 30 Mar 2009
• Does study design influence outcome?. The effects of placebo control and treatment duration in antidepressant trials. 22 Mar 2009
• Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits. 27 Feb 2009
• Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. 15 Feb 2009
• Can we achieve neuroprotection with currently available anti-parkinsonian interventions? 15 Feb 2009
• Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. 15 Feb 2009
• [Antidepressive pharmacotherapy. In slight and severe disease, young and old] 30 Jan 2009
• Treatment of early Parkinson's disease. Part 1. 27 Jan 2009
• Treatment of early Parkinson's disease. Part 2. 27 Jan 2009

See a longer list of these articles.

Technical information about 'Monoamine Oxidase Inhibitors'

Definition: A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)

Registry Number: 0

Descriptor UI: D008996

Alternative terms: Monoamine Oxidase Inhibitors; Inhibitors, Monoamine Oxidase; MAO Inhibitors; Inhibitors, MAO; Monoamine Oxidase Inhibitor; Inhibitor, Monoamine Oxidase; Reversible Inhibitors of Monoamine Oxidase; Reversible Inhibitor of Monoamine Oxidase; RIMA (Reversible Inhibitor of Monoamine Oxidase A);

Related Mesh Headings: Antidepressive Agents;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.519.389.616;

Technical Notes: DF: MAO INHIB